NCI-2022-05168

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1

In this research study, they want to see if a new medicine called sacituzumab govitecan can help people with metastatic triple-negative breast cancer. They're looking at people whose cancer cells don't have something called PD-L1. PD-L1 is like a guard protin on special cells that help our body's defense system work. When PD-L1 is blocked, it's like taking off the brakes from our defense system, and it helps our immune cells fight cancer better. So, they're testing this new medicine to see if it can help people with this kind of breast cancer that doesn't have PD-L1. The medicine is a mix of something called an antibody and a drug.

Metastatic: cancer that has spread from its original location or organ to other parts of the body.

Triple-Negative: It is a type of breast cancer in which cells do not have estrogen receptors (ER), progesterone receptors (PR), and HER-2 receptors.

Antibody: Antibodies are part of our body's defense system. They are proteins found in the blood that can specifically recognize and remove foreign substances like bacteria or cancer in the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05382299

NCI-2022-05168

Clinical Trial Site: Columbia

To see all available clinical trials click here.